Strategy for Treating MAFLD: Electroacupuncture Alleviates Hepatic Steatosis and Fibrosis by Enhancing AMPK Mediated Glycolipid Metabolism and Autophagy in T2DM Rats

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Sep 11

PMID 39261952

Authors

Haoru Duan

Shanshan Song

Rui Li

Suqin Hu

Shuting Zhuang

Shaoyang Liu

Xiaolu Li

Wei Gao

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies have highlighted type 2 diabetes (T2DM) as a significant risk factor for the development of metabolic dysfunction-associated fatty liver disease (MAFLD). This investigation aimed to assess electroacupuncture's (EA) impact on liver morphology and function in T2DM rats, furnishing experimental substantiation for its potential to stall MAFLD progression in T2DM.

Methods: T2DM rats were induced by a high-fat diet and a single intraperitoneal injection of streptozotocin, and then randomly assigned to five groups: the T2DM group, the electroacupuncture group, the metformin group, combination group of electroacupuncture and metformin, combination group of electroacupuncture and Compound C. The control group received a standard diet alongside intraperitoneal citric acid - sodium citrate solution injections. After a 6-week intervention, the effects of each group on fasting blood glucose, lipids, liver function, morphology, lipid droplet infiltration, and fibrosis were evaluated. Techniques including Western blotting, qPCR, immunohistochemistry, and immunofluorescence were employed to gauge the expression of key molecules in AMPK-associated glycolipid metabolism, insulin signaling, autophagy, and fibrosis pathways. Additionally, transmission electron microscopy facilitated the observation of liver autophagy, lipid droplets, and fibrosis.

Results: Our studies indicated that hyperglycemia, hyperlipidemia and IR promoted lipid accumulation, pathological and functional damage, and resulting in hepatic steatosis and fibrosis. Meanwhile, EA enhanced the activation of AMPK, which in turn improved glycolipid metabolism and autophagy through promoting the expression of PPARα/CPT1A and AMPK/mTOR pathway, inhibiting the expression of SREBP1c, PGC-1α/PCK2 and TGFβ1/Smad2/3 signaling pathway, ultimately exerting its effect on ameliorating hepatic steatosis and fibrosis in T2DM rats. The above effects of EA were consistent with metformin. The combination of EA and metformin had significant advantages in increasing hepatic AMPK expression, improving liver morphology, lipid droplet infiltration, fibrosis, and reducing serum ALT levels. In addition, the ameliorating effects of EA on the progression of MAFLD in T2DM rats were partly disrupted by Compound C, an inhibitor of AMPK.

Conclusions: EA upregulated hepatic AMPK expression, curtailing gluconeogenesis and lipogenesis while boosting fatty acid oxidation and autophagy levels. Consequently, it mitigated blood glucose, lipids, and insulin resistance in T2DM rats, thus impeding liver steatosis and fibrosis progression and retarding MAFLD advancement.

References

Liang J, Xu Z, Ding Z, Lu Y, Yu Q, Werle K . Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun. 2015; 6:7926. DOI: 10.1038/ncomms8926. View

Kang Y, Li M, Yan W, Li X, Kang J, Zhang Y . Electroacupuncture alters the expression of genes associated with lipid metabolism and immune reaction in liver of hypercholesterolemia mice. Biotechnol Lett. 2007; 29(12):1817-24. DOI: 10.1007/s10529-007-9482-7. View

Ni H, Woolbright B, Williams J, Copple B, Cui W, Luyendyk J . Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol. 2014; 61(3):617-25. PMC: 4143992. DOI: 10.1016/j.jhep.2014.04.043. View

Muthiah M, Cheng Han N, Sanyal A . A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know. Diabetes Obes Metab. 2021; 24 Suppl 2:3-14. DOI: 10.1111/dom.14521. View

Jiang H, Shang Z, You L, Zhang J, Jiao J, Qian Y . Electroacupuncture Pretreatment at Zusanli (ST36) Ameliorates Hepatic Ischemia/Reperfusion Injury in Mice by Reducing Oxidative Stress via Activating Vagus Nerve-Dependent Nrf2 Pathway. J Inflamm Res. 2023; 16:1595-1610. PMC: 10120822. DOI: 10.2147/JIR.S404087. View

Kawabata T, Yoshimori T . Autophagosome biogenesis and human health. Cell Discov. 2020; 6(1):33. PMC: 7264243. DOI: 10.1038/s41421-020-0166-y. View

Sekizkardes H, Chung S, Chacko S, Haymond M, Startzell M, Walter M . Free fatty acid processing diverges in human pathologic insulin resistance conditions. J Clin Invest. 2020; 130(7):3592-3602. PMC: 7324196. DOI: 10.1172/JCI135431. View

Sayeed M, Gautam S, Verma D, Afshan T, Kumari T, Srivastava A . A collagen domain-derived short adiponectin peptide activates APPL1 and AMPK signaling pathways and improves glucose and fatty acid metabolisms. J Biol Chem. 2018; 293(35):13509-13523. PMC: 6120198. DOI: 10.1074/jbc.RA118.001801. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

10.

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

11.

Santos R, Valenti L, Romeo S . Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019; 282:110-120. DOI: 10.1016/j.atherosclerosis.2019.01.029. View

12.

Khomich O, Ivanov A, Bartosch B . Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis. Cells. 2019; 9(1). PMC: 7016711. DOI: 10.3390/cells9010024. View

13.

Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F . Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015; 21(5):739-46. DOI: 10.1016/j.cmet.2015.04.004. View

14.

Grefhorst A, Van de Peppel I, Larsen L, Jonker J, Holleboom A . The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2021; 11:601627. PMC: 7883485. DOI: 10.3389/fendo.2020.601627. View

15.

Czaja M . Function of Autophagy in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016; 61(5):1304-13. PMC: 4838507. DOI: 10.1007/s10620-015-4025-x. View

16.

Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R . Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54(12):3541-6. DOI: 10.2337/diabetes.54.12.3541. View

17.

Ahmad E, Lim S, Lamptey R, Webb D, Davies M . Type 2 diabetes. Lancet. 2022; 400(10365):1803-1820. DOI: 10.1016/S0140-6736(22)01655-5. View

18.

Liu T, Xu L, Wang C, Chen K, Xia Y, Li J . Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-β1/Smads pathway through shikonin. J Gastroenterol Hepatol. 2018; 34(1):263-276. DOI: 10.1111/jgh.14299. View

19.

Morgan M, Liu Z . Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2010; 21(1):103-15. PMC: 3193400. DOI: 10.1038/cr.2010.178. View

20.

Zhang E, Yin S, Song X, Fan L, Hu H . Glycycoumarin inhibits hepatocyte lipoapoptosis through activation of autophagy and inhibition of ER stress/GSK-3-mediated mitochondrial pathway. Sci Rep. 2016; 6:38138. PMC: 5128870. DOI: 10.1038/srep38138. View